Does rapamycin extend lifespan in humans?

Q: Does rapamycin extend lifespan in humans?

No study has directly tested this — a human lifespan trial would take decades. Rapamycin reliably extends lifespan in mice (Tier C evidence, e.g. a 9-14% median lifespan increase in HAR2009). In humans, the evidence so far covers biomarkers, immune/cardiovascular/skin parameters, and short-term safety (Tier A-B), not an actual mortality outcome.

Short answer: we don't know yet, and no study has directly tested it. What's well established is that rapamycin extends lifespan in mice (Tier C, animal evidence). In humans, the evidence so far covers biomarkers and short-term safety, not actual lifespan — a human lifespan trial would take decades. The strongest human evidence to date is a systematic review (Tier A) reporting improvements in immune, cardiovascular, and skin parameters, not a mortality outcome.

The evidence, by tier

Tier	What it means	Studies
A	Systematic review of human data	1
B	Direct human evidence	7
C	Animal in vivo	14
D	Mechanistic / in vitro / review	15

Rapamycin is the most-studied intervention in this Atlas for its effect on the mTOR pathway (38 studies total).

What each tier actually shows

LEE2024 A — the first systematic review of rapamycin/rapalogs in humans specifically for aging; found improvements in immune, cardiovascular, and skin parameters — biomarkers and safety, not a lifespan endpoint.
MOE2025 B — a 48-week randomized controlled trial (n=114) found NO significant change in its primary endpoint, visceral fat by DXA (p=0.942) — a null result worth knowing about, since not every human trial confirms the mouse findings.
KRA2018 B — low-dose rapamycin was tolerable in older adults over 8+ weeks, with only minor adverse events.
HAR2009 C — rapamycin fed starting at 600 days of age (late-middle-age for a mouse) extended median lifespan by 9–14% in both sexes.
BIT2016 C — just 3 months of rapamycin late in life increased subsequent life expectancy by up to 60% — the lifespan benefit doesn't require lifelong dosing.
SAR2006 D — long-term dosing also suppresses mTORC2 signaling in many cell types — the likely mechanism behind the insulin resistance seen with daily dosing.

The honest gap

Nobody has run — or can easily run — a randomized trial that follows healthy humans on rapamycin for the decades it would take to measure an actual lifespan effect. Every human data point so far is a proxy: biomarkers, short-term safety, or one physiological outcome like visceral fat. Whether mTORC1-selective (mTORC2-sparing) dosing could capture the mouse-study longevity signal without the human metabolic downside is one of the Atlas's 10 open questions, each paired with a proposed experiment. See the full open question.

Related entities

Open in the Atlas explorer